The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 553-559

  Overman, M J ^a   Feng, L ^a   Pro, B ^a   McLaughlin, P ^a   Hess, M ^a   Samaniego, F ^a   Younes, A ^a   Romaguera, J E ^a   Hagemeister, F B ^a   Kwak, L ^a   Cabanillas, F ^b   Rodriguez, M A ^a   Fayad, L E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Auxilio Mutuo Cancer Center   (Puerto Rico)

Author keywords

CHOP; Follicular lymphoma grade 3; Outcome; Rituximab; Therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONFIDENCE INTERVAL; FAILURE FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PREDNISONE; PROPORTIONAL HAZARDS MODELS; SALVAGE THERAPY; SURVIVAL RATE; VINCRISTINE;

EID: 40349086087     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm511     Document Type: Article

References (31)

1. Armitage JO, MP, Harris NL et al. Non-Hodgkin's Lymphoma. Philadelphia, PA: Lippincott Williams and Wilkins 2001.
2. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project [editorial]. N Engl J Med 1993; 329: 987-994.
4. Martin AR, Weisenburger DD, Chan WC et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995; 85: 3671-3678.
5. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's:LYmphoma Pathologic Classification Project [editorial]. Cancer 1982; 49: 2112-2135.
6. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
7. Nathwani BN, HN, Weisenburger DD et al. Follicular Lymphoma. Lyon, France: IARC Press 1994.
8. Ott G, Katzenberger T, Lohr A et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002; 99: 3806-3812.
9. Wendum D, Sebban C, Gaulard P et al. Follicular large-cell lymphoma treated with intensive chemotherapy: An analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma, Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1654-1663.
10. Glick JH, McFadden E, Costello W et al. Nodular histiocytic lymphoma: factors influencing prognosis and implications for aggressive chemotherapy. Cancer 1982; 49: 840-845.
11. Osborne CK, Norton L, Young RC et al. Nodular histiocytic lymphoma: An aggressive nodular lymphoma with potential for prolonged disease-free survival. Blood 1980; 56: 98-103.
12. Bartlett NL, Rizeq M, Dorfman RF et al. Follicular large-cell lymphoma: intermediate or low grade? J Clin Oncol 1994; 12: 1349-1357.
13. Ganti AK, Weisenburger DD, Smith LM et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: The Nebraska Lymphoma Study Group Experience. Ann Oncol 2006; 17: 920-927.
14. Kantarjian HM, McLaughlin P, Fuller LM et al. Follicular large cell lymphoma: Analysis and prognostic factors in 62 patients. J Clin Oncol 1984; 2: 811-819.
15. Rigacci L, Federico M, Martelli M et al. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma 2003; 44: 1911-1917.
16. Rodriguez J, McLaughlin P, Hagemeister FB et al. Follicular large cell lymphoma: An aggressive lymphoma that often presents with favorable prognostic features. Blood 1999; 93: 2202-2207.
17. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine; and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP-alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
18. Czuczman MS, Weaver R, Alkuzweny B et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's. lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711-4716.
19. Forstpointner R, Dreyling M, Repp R et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064-3071.
20. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
21. Sarma A, RA, Cabanillas F et al. A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 122: Abstr 8066.
22. Romaguera JE, McLaughlin P, North L et al. Multivarlate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model. J Clin Oncol 1991; 9: 762-769.
23. Cheson BD, Horning SJ, Coiffier B et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244-1253.
24. Ghielmini M, Mora O. Does the FLIPI apply to grade 3 follicular lymphoma? Blood 2005; 105: 4892 author reply 4892-4893.
25. Horning SJ. Something old, something few, something subjective, something deja vu. J Clin Oncol 2003; 21: 1-2.
26. Chau I, Jones R, Cunningham D et al. Outcome of follicular lymphoma grade 3: Is anthracycline necessary as front-line therapy? Br J Cancer 2003; 89: 36-42.
27. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximalb versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MlnT) Group. Lancet Oncol 2006; 7: 379-391.
28. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
29. Buske C, Hoster E, Dreyling M et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504-1508.
30. Bosga-Bouwer AG, van Imhoff GW, Boonstra R et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: T(14;18) and 3q27 are mutually exclusive. Blood 2003; 101: 1149-1154.
31. Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study, Blood 2006; 107: 4207-4213.